* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immun...
* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI sol...
* Lunit invited to join the World Economic Forum's Global Innovators Community, an invitation-onl...
* Lunit participates in the 20th Asian Oceanian Congress of Radiology and 78th Annual Meeting of ...
* Joint study with Massachusetts General Hospital proves that Lunit's AI-powered chest x-ray anal...
* Lunit participated in the "Indonesia AI Healthcare Course," organized by South Korean Ministry ...
* Lunit to present five posters at ESMO 2022 featuring the company's AI-biomarker platform * St...
* Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan F...
* Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-yea...
* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence ...
SEOUL, South Korea, July 21, 2022 /PRNewswire/ -- Lunit, a global provider of AI-powered cancer sol...
* Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000 * To be listed ...
* Lunit and Cathay Life Insurance signed a license agreement to officially adopt Lunit's AI solut...
* Lunit and FujiFilm Thailand to supply Lunit INSIGHT CXR and Lunit INSIGHT MMG to one of SEA's l...
* First Korean healthcare company to obtain "AA-AA" ratings in technology assessment for its FDA-...
* Lunit to showcase 7 poster presentations and 4 online publications, the company's largest publi...
* Study findings show that Lunit's AI-powered PD-L1 TPS analyzer minimizes interpretation discrep...
* 7 poster presentations and 4 online publications, including research on AI biomarkers, have bee...
* Lunit gets greenlight to accelerate listing on the KOSDAQ market * First Korean healthcare com...
* Lunit to present two abstracts about its AI-biomarker for immunotherapy, Lunit SCOPE IO * Lun...
